Myeloma

Darzalex Faspro has received FDA approval for use in combination with pomalidomide and dexamethasone for patients with multiple myeloma who previously received one line of therapy.

Donald Rumsfeld, who died from multiple myeloma, served as secretary of defense under Presidents Gerald R. Ford and George W. Bush.

Recent findings merit further study of the immunosuppressive drug as therapy in patients with multiple myeloma.

Results from a recent study strongly support a treatment regimen of Darzalex with Revlimid and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

Treatment with an investigational drug induced high response rates in patients with relapsed or refractory multiple myeloma.

Patients with relapsed/refractory myeloma who were previously treated with three or more therapies responded to an infusion of a novel CAR-T cell therapy up to 18 months with no new side effects compared with 12-month results of this study.

The study’s lead author noted that a survival outcome, along with other results, was similar among the two groups.

After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.

A single infusion of a novel CAR-T cell therapy was associated with early and deep responses to treatment among a certain group of patients with multiple myeloma.

Donna and Dr Gasparetto close the discussion by highlighting the importance of physicians utilizing their patients, as well as patients being involved with their multiple myeloma treatment.

Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies.

Researchers have developed Myeloma Drug Sensitivity Testing to determine which medications will be most effective with minimal side-effects.

Cristina Gasparetto, MD, discusses Donna’s relationship with the drug carfilzomib for multiple myeloma therapy, as well as her second relapse.

Donna and Dr Gasparetto converse about the many first- and second-line therapies for multiple myeloma.

Cristina Gasparetto, MD, details typical multiple myeloma maintenance in comparison with Donna’s therapies, and Donna tells us about her first relapse with multiple myeloma.

We learn more about Donna’s 2 transplants, her chemotherapy, and how they impacted her quality of life.

Donna discusses her multiple myeloma diagnosis and the start of her treatment, while Dr Gasparetto educates on the importance of transplants.

Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.

Patients with cancer can advocate for themselves by researching their illnesses and treatments before an appointment, so they’re able to ask better questions, says an expert from the HealthTree Foundation for Multiple Myeloma.

When a patient is first diagnosed with myeloma, they should seek out various opinions until they find a specialist that is well-versed in their cancer type, says an expert from the HealthTree Foundation & Myeloma Crowd.

New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.

All patients with multiple myeloma have had MGUS, so what is it?

There is a difference between patient and oncologists regarding prognosis, and patients are lacking understanding of prognosis and interventions needed to help them make more informed treatment choices.

The Food and Drug Administration’s recent approval of Abecma is an extremely significant development for patients with heavily pretreated multiple myeloma, according to an expert from the Dana-Farber Cancer Institute.

Most patients with newly diagnosed multiple myeloma treated with a combination of Kyprolis, Revlimid, dexamethasone and Darzalex achieved minimal residual disease negativity during a median follow-up of 11 months.